Stage I Bladder Cancer
6
0
0
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
33.3%
2 terminated out of 6 trials
60.0%
-26.5% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer
Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery
Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
Gene Therapy in Treating Patients With Advanced Bladder Cancer